论文部分内容阅读
目的:对孟鲁司特钠在过敏性紫癜患儿治疗中的临床运用效果探析。方法:选取2013年6月至2016年2月潮州市中心医院儿所收治的200例过敏性紫癜患儿,按随机数字表法分成对照组与治疗组,对照组患者予以常规治疗(抗过敏、抗感染、对症支持),治疗组患者在此基础之上给予以孟鲁司特钠治疗(2~6岁4 mg/晚、6~14岁5 mg/晚),持续治疗4周。比较两组患者的临床疗效,且观察治疗前后患儿各项尿蛋白指标的变化。结果:治疗组治疗有效率94.0%高于对照组72.0%,差异具有统计学意义(P<0.05);治疗组患儿的皮肤紫癜、腹痛以及关节痛等症状的消失时间均短于对照组患者,差异具有统计学意义(P<0.05);治疗组患者治疗后的免疫球蛋白G(Ig G)、微量白蛋白(Alb)、转铁蛋白(TRF)以及β2-微球蛋白(β2-MG)等指标优于本组治疗前及对照组,差异具有统计学意义(P<0.05)。结论:对过敏性紫癜患儿采取孟鲁司特钠治疗,疗效甚佳,可有效改善患者的临床症状,且不良反应少。
Objective: To investigate the clinical effect of montelukast sodium in the treatment of children with Henoch-Schonlein purpura. Methods: 200 children with Henoch-Schonlein purpura who were admitted to Chaozhou Central Hospital from June 2013 to February 2016 were randomly divided into control group and treatment group according to random number table, and patients in control group were treated routinely (anti-allergy, Anti-infective and symptomatic support. Patients in the treatment group were treated with montelukast sodium (4 mg / night at 2 to 6 years and 5 mg / night at 6 to 14 years) for 4 weeks. The clinical efficacy of the two groups was compared, and the changes of urinary protein in children before and after treatment were observed. Results: The effective rate of treatment group was 94.0% higher than that of control group (72.0%), the difference was statistically significant (P <0.05); the disappearance time of skin purpura, abdominal pain and joint pain were shorter in treatment group than in control group , The difference was statistically significant (P <0.05). After treatment, the immunoglobulin G (Ig G), microalbumin (Alb), transferrin (TRF) and β2-microglobulin ) And other indicators were better than the group before treatment and control group, the difference was statistically significant (P <0.05). Conclusion: Montelukast treatment of children with Henoch-Schonlein purpura has good curative effect, which can effectively improve the clinical symptoms of patients with less adverse reactions.